{
    "clinical_study": {
        "@rank": "124386", 
        "arm_group": {
            "arm_group_label": "Octreotide", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The research study is designed to test how a medication called octreotide affects the\n      motility (contraction or squeezing) of the colon (large intestine).  Investigators are\n      investigating whether octreotide can increase contraction and movement in the colon."
        }, 
        "brief_title": "Effect of Octreotide on the Colonic Motility in Pediatric Patients", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Actual"
        }, 
        "condition": "Colonic Motility Index", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female and undergoing colonic manometry for a routinely accepted indication\n             including:  evaluation of chronic constipation, unexplained abdominal distension\n             (Should have had previous diagnostic work up), recurrent fecal impaction, post\n             Hirschsprung's disease repair, chronic intestinal pseudo-obstruction, or suspected\n             colonic dysmotility of any other cause.\n\n          -  Children aged 12 months or older who are undergoing colonic motility under the\n             supervision of Dr. Joseph Croffie at Riley Hospital.\n\n          -  In the investigator's judgment, parent(s)/guardian(s) is mentally competent to\n             provide informed consent to participate in the study.\n\n        Exclusion Criteria:\n\n          -  \u2022 Subjects with known or suspected allergy to octreotide.\n\n               -  Subjects with known prolonged QTc Syndrome or highest risk QTc-Prolonging Agents\n                  (including mifepristone).\n\n               -  Subjects with known history of ventricular arrhythmia.\n\n               -  Subjects with history of any organ transplant who are taking cyclosporine at the\n                  time of the motility study.\n\n               -  Subjects with history of small bowel transplant.\n\n               -  Subjects less than 12 months old.\n\n               -  Subjects with severe renal impairment\n\n               -  Subjects with severe hepatic impairment\n\n               -  Subjects taking bromocriptine, insulin, oral hypoglecemic agents, beta blockers,\n                  calcium channel blockers, quinidine, terfenadine, pimozide, sildenafil,\n                  tadalafil, and any agents to control fluid and electrolyte imbalance"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "1 Year"
        }, 
        "enrollment": {
            "#text": "13", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01917773", 
            "org_study_id": "1305011397"
        }, 
        "intervention": {
            "arm_group_label": "Octreotide", 
            "intervention_name": "Octreotide", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Octreotide"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Indianapolis", 
                    "country": "United States", 
                    "state": "Indiana", 
                    "zip": "46202"
                }, 
                "name": "Motility Laboratory, Division of Pediatric Gastroenterology, Hepatology and Nutrition at the James Whitcomb Riley Hospital for Children,"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Effect of Octreotide on the Colonic Motility in Pediatric Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Colonic motility index", 
            "safety_issue": "Yes", 
            "time_frame": "participants will be followed for the duration of colonic motility study ie five hours."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01917773"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Indiana University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Indiana University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}